Cook S D, Baffes G C, Wolfe M W, Sampath T K, Rueger D C, Whitecloud T S
Department of Orthopaedic Surgery, Tulane University School of Medicine, New Orleans, Louisiana 70112.
J Bone Joint Surg Am. 1994 Jun;76(6):827-38. doi: 10.2106/00004623-199406000-00006.
A rabbit ulnar non-union model was used to evaluate the effect of recombinant human osteogenic protein-1 on the healing of a large segmental osteoperiosteal defect. A 1.5-centimeter segmental defect was created in the mid-part of the ulnar shaft of adult rabbits. The defect was filled with an implant containing either recombinant human osteogenic protein-1 or naturally occurring bovine osteogenic protein. The recombinant human osteogenic protein-1 implants consisted of a carrier of 125 milligrams of demineralized, guanidine-extracted, insoluble rabbit bone matrix (the collagen carrier), reconstituted with 3.13, 6.25, 12.5, twenty-five, fifty, 100, 200, 300, or 400 micrograms of recombinant human osteogenic protein-1. Animals that received recombinant human osteogenic protein-1 were compared with animals that received an implant of 250 micrograms of a preparation of naturally occurring bovine osteogenic protein mixed with the collagen carrier. Limbs that served as controls received either the collagen carrier alone or no implant at all. The treated and the untreated defects were examined radiographically and histologically at eight or twelve weeks after implantation. Mechanical testing was performed on six animals. All implants of recombinant human osteogenic protein-1, except for those containing 3.13 micrograms of the substance, induced complete radiographic osseous union within eight weeks. The defects that were treated with an implant of bovine osteogenic protein also healed within this time-period. The bone induced by both types of implants had new cortices with advanced remodeling and marrow elements. Histological evaluation of this new bone at eight weeks postoperatively revealed primarily lamellar bone, with the formation of new cortices and normal-appearing marrow elements. The average torsional strength and energy-absorption capacity of the union induced by recombinant human osteogenic protein-1 was comparable with that of intact bone. The control defects that had been implanted with collagen carrier alone and those with no implant showed no bridging of the defect.
采用兔尺骨骨不连模型评估重组人骨生成蛋白-1对大段骨膜骨缺损愈合的影响。在成年兔尺骨干中部制造一个1.5厘米的节段性缺损。缺损处植入含有重组人骨生成蛋白-1或天然牛骨生成蛋白的植入物。重组人骨生成蛋白-1植入物由125毫克脱矿质、胍提取、不溶性兔骨基质(胶原载体)组成,再与3.13、6.25、12.5、25、50、100、200、300或400微克重组人骨生成蛋白-1重构。将接受重组人骨生成蛋白-1的动物与接受植入250微克天然牛骨生成蛋白制剂与胶原载体混合的动物进行比较。作为对照的肢体单独接受胶原载体或根本不植入。在植入后8周或12周对治疗和未治疗的缺损进行影像学和组织学检查。对6只动物进行力学测试。除含有3.13微克该物质的植入物外,所有重组人骨生成蛋白-1植入物在8周内均诱导完全的影像学骨愈合。用牛骨生成蛋白植入物治疗的缺损在该时间段内也愈合。两种植入物诱导的骨均有新的皮质,伴有高级重塑和骨髓成分。术后8周对这种新骨的组织学评估显示主要为板层骨,伴有新皮质的形成和外观正常的骨髓成分。重组人骨生成蛋白-1诱导的骨愈合的平均抗扭强度和能量吸收能力与完整骨相当。单独植入胶原载体以及未植入的对照缺损均未显示缺损处有骨桥形成。